Medtronic is the global market leader in deep brain stimulation (DBS), having commercialized the first FDA-approved DBS system for essential tremor in 1997. The Neuromodulation division develops the Percept PC, the first FDA-approved DBS system with bidirectional LFP sensing (BrainSense), enabling closed-loop and adaptive stimulation. Medtronic's DBS installed base of over 200,000 patients worldwide gives it unparalleled long-term outcome data. The company also develops spinal cord stimulation, peripheral nerve stimulation, and is investing in closed-loop adaptive DBS using beta-band biomarkers.